Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Helus Pharma reiterated that topline data from the APPROACH Phase 3 study of HLP003 in adjunctive treatment of major depressive disorder remains on track for Q4 2026. The company also detailed its next HLP004 Phase 2 monotherapy study for generalized anxiety disorder, now expected to start in Q1 2027 with approximately 144 participants randomized 1:1 to 30 mg HLP004 or placebo.
Key figures
- Drug Name
- HLP003
- Phase Of Trial
- Phase 3
- Hlp004 dose
- 30 mg
- Nda filing target
- 2028
- Hlp003 designation
- FDA Breakthrough Therapy
- Approach enrollment
- 223
- Phase3 topline readout
- Q4 2026
- Hlp004 phase2 initiation
- Q1 2027
- Hlp004 phase2 planned enrollment
- 144
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.